Specify a stock or a cryptocurrency in the search bar to get a summary
Invion Ltd
IVXInvion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, and solid cancers, such as lung, ovarian, anogenital, and glioblastoma multiforme cancers. It has a research and development agreement with Hudson Institute of Medical Research to develop a novel photosensitiser for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia. Address: 100 Albert Road, Melbourne, VIC, Australia, 3205
Analytics
WallStreet Target Price
0.17 AUDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures IVX
Dividend Analytics IVX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History IVX
Stock Valuation IVX
Financials IVX
Results | 2019 | Dynamics |